Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.
The company has discovered several promising new drug candidates. In collaboration with some of the most prestigious research institutions in the world, Flavocure is advancing these candidates through clinical research. Preliminary data indicate that Flavocure’s drug candidates possess activity against known driver mutations and targets implicated in cancer.
Caflanone is Flavocure’s lead drug candidate and received FDA Orphan Drug Designation in 2019 for pancreatic cancer.
In addition to pancreatic cancer, Flavocure’s drug candidates have demonstrated activity in a variety of cancers, including Glioblastoma (an aggressive form of brain cancer), Acute Myeloid Leukemia, and Multiple Myeloma.
Product | Target | Disease | Developmental Stage | Worldwide Rights | Research Partners |
---|---|---|---|---|---|
Caflanone | CSF1R | Pancreatic Cancer | IND ready FDA-ORPHAN Drug Designation | ![]() | Ongoing |
Caflanone | CSF1R | GBM/Myeloma | Pre-Clinical | ![]() | Ongoing |
Cresorol | FLT3 | AML | FDA-ORPHAN Drug Designation | ![]() | Ongoing |
In the US, SEER reported pancreatic cancer as the 11th most common cancer with 60,430 new cases and 48,220 deaths in 2022. Pancreatic cancer statistics highlight a dire need for transformative therapies for this lethal disease
2022 US Pancreatic Cancer Statistics
Glioblastoma or brain cancer is considered a very dire prognosis for patients. In the US, SEER reported cancers of the brain and other nervous systems to be 16th most common cancer with 25,051 new cases and 18,280 deaths in 20222.
2022 Brain and other nervous system cancer statistics
Myeloma is a type of blood cancer that develops from plasma cells, a type of white blood cells. In the US, SEER reported Myeloma to be the 14th most common cancer with 34,470 new cases and 12,640 deaths in 2022.
2022 Myeloma statistics
AML is a type of blood cancer that starts in the blood forming cells of the bone marrow. In the US SEER reported AML to be relatively rare cancer with 20,050 new cases and 11,540 deaths in 2022
2022 AML statistics
Subscribe to Receive News from Flavocure Biotech
Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.
Get all latest news from Flavocure Biotech